Craft
Cogent Biosciences

Cogent Biosciences

Phase I Trials Products

3

Mar, 2018

Revenue

$8.4 M

FY, 2017

Market Capitalization

$575 M

2023-01-27

Cogent Biosciences Summary

Company summary

Overview
Cogent Biosciences (formerly known as Unum Therapeutics) uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.
Type
Public
Status
Active
Founded
2014
HQ
Cambridge, MA, US | view all locations
Website
https://www.cogentbio.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key people

  • John Green

    John Green, Chief Financial Officer

    • Erin Schellhammer

      Erin Schellhammer, Chief People Officer

      • Peter Harwin

        Peter Harwin, Director

        • Chris Cain

          Chris Cain, Director

          Operating MetricsView all

          Phase I Trials Products

          3

          Mar, 2018

          Pre-Clinical Phase Products

          1

          Mar, 2018

          LocationsView all

          1 location detected

          • Cambridge, MA HQ

            United States

            200 Cambridgepark Dr #3100

          Cogent Biosciences Financials

          Summary financials

          Revenue (FY, 2017)
          $8.4M
          Net income (FY, 2017)
          ($25.5M)
          Cash (FY, 2017)
          $28.3M
          EBIT (FY, 2017)
          ($26.2M)

          Footer menu